Načítá se...
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
BACKGROUND: Mantle-cell lymphoma is generally incurable. Initial treatment is not standardized but usually includes cytotoxic chemotherapy. Lenalidomide, an immunomodulatory compound, and rituximab, an anti-CD20 antibody, are active in patients with recurrent mantle-cell lymphoma. We evaluated lenal...
Uloženo v:
| Vydáno v: | N Engl J Med |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4710541/ https://ncbi.nlm.nih.gov/pubmed/26535512 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1505237 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|